Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data.
Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, Ledet E, Akerele A, Moradi Tuchayi A, Lawhn-Heath C, Wang T, Carducci MA, Pomper MG, Paller CJ, Czernin J, Solnes LB, Hope TA, Sartor O, Calais J, Gafita A.
Murthy V, et al. Among authors: paller cj.
J Nucl Med. 2024 Nov 1;65(11):1740-1744. doi: 10.2967/jnumed.124.267816.
J Nucl Med. 2024.
PMID: 39327018
Clinical Trial.